Latest

Nov 29, 2016
Biosimilars are gaining more support among payers and physicians, but more needs to be done to explain their benefits as well as their safety and efficacy profiles, writes Barbara Testa.
Nov 29, 2016
However conservative and heavily regulated the drugs business, it too must transform itself to exploit digital opportunities — if only to ward off disruption, says Elvis Paćelat.
Nov 22, 2016
“Volume is not a dirty word” was outgoing GSK head Sir Andrew Witty’s key message at this month's FT Global Pharmaceutical Conference in London.
Nov 18, 2016
Biopharma companies should no longer consider FDA an obstacle to innovation and in need of major reform, according to Jim Greenwood, President of BIO.
Nov 11, 2016
Pharmaceutical Executive
An industry-based working group presents a common standards and definition framework for “Access” competencies in pharma.
Oct 31, 2016
By Pharmaceutical Executive Editors
Novartis and Bristol-Myers Squibb were among the companies honored with Prix Galien Foundation “Discovery of the Decade” Awards in New York last week.
Oct 24, 2016
FDA’s new Office of Tissues and Advanced Therapies will oversee a growing range of cellular and genetic products.
Oct 12, 2016
Pharmaceutical Executive
The potential collapse of the CETA agreement jeopardizes EU’s overall trade footing.
Aug 31, 2016
For generic firms, Inter Partes Reviews (IPRs) are a cost-effective way to clear out FDA Orange Book-listed patents before or during litigation; for originator companies, they pose a threat to valuable patent portfolios. Steve Maebius reports.
Aug 24, 2016
Traditional sales and pricing practices face legal challenges and political backlash, writes Jill Wechsler.
native1_300x100
lorem ipsum